Yuki Gosei Kogyo Co., Ltd.
Q1 FY2027 Financial Summary
Revenue for the first quarter of FY2027 was JPY 4,284 million, a 7.2% increase YoY. Net income was JPY 200 million, a 108.3% increase YoY. Although revenue increased, operating profit declined due to rising costs. The full-year earnings forecast is currently undecided.
Key Figures
- Revenue: JPY 4,284 million (YoY+7.2%)
- Net income: JPY 200 million (YoY+108.3%)
- Operating income: JPY 41 million (YoY-69.4%)
AI要約
Financial Performance Overview
Organic Synthesis Pharmaceutical Industries reported revenue of JPY 4,284 million for the first quarter of FY2027, marking a 7.2% increase compared to the same period last year. Operating profit decreased sharply by 69.4%, amounting to JPY 41 million, primarily due to rising costs. Net income rose by 108.3% to JPY 200 million, driven by increased sales and improved cost management. The revenue growth is mainly attributed to strong performance in the chemical products segment.
Future Outlook and Investor Implications
While the full-year earnings forecast remains undecided, the increases in revenue and net income are positive indicators. Attention should be paid to rising costs and market environment changes; however, prospects for long-term growth through expansion in the chemical segment and continued cost control remain promising. Investors should monitor upcoming performance trends and cost management strategies.
Organic Synthesis Pharmaceutical Industries Co., Ltd.
Company overview · Stock price · Financial data · All IR
